| Variable | Patients | NRs | SVRs |
| No. | 40 | 14 | 26 |
| Gender (male, n (%)) | 26 (65) | 9 (64) | 17 (65) |
| Age (years) | 47.4 (8.6) | 46.5 (7.1) | 47.9 (9.4) |
| Source of infection (n (%)) | |||
| Blood transfusion | 11 (27.5) | 3 (21.4) | 8 (30.8) |
| Intravenous drug use | 13 (32.5) | 5 (35.7) | 8 (30.8) |
| Unknown | 16 (40.0) | 6 (42.9) | 10 (38.5) |
| ALT (IU/l, median) | 120 (57) | 132 (86) | 114 (43) |
| HCV genotype (n) | |||
| 1 | 24 | 13 | 11 |
| 2 | 3 | 0 | 3 |
| 3 | 8 | 0 | 8 |
| 4 | 4 | 1 | 3 |
| 5 | 1 | 0 | 1 |
| Stage (n) | |||
| F1 | 13 | 1 | 12 |
| F2 | 15 | 7 | 8 |
| F3 | 8 | 4 | 4 |
| F4 | 4 | 2 | 2 |
ALT, alanine aminotransferase; HCV, hepatitis C virus; NRs, non-responders; SVRs, sustained virological responders.